phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»phkinetica-161Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОКИНЕТИКАCLINICAL PHARMACOKINETICSТерапевтический лекарственный мониторинг метотрексата при применении его в высоких дозах для лечения остеосаркомы у детейTherapeutic drug monitoring of methotrexate after its administration in high doses for osteosarcoma treatment in childrenСтрижевскаяАлександра МихайловнаStrizhevskayaA. M.Strizhevsky@yandex.ruГоловняЕ. Г.GolovnyaE. G.noemail@neicon.ruКулешоваИ. С.KuleshovaI. S.noemail@neicon.ruДзампаевА. З.DzampaevaA. Z.noemail@neicon.ruБайковаВ. Н.BaykovaV. N.noemail@neicon.ruФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина»РоссияFSBSI «RONC N.N. Blokhina»Russian Federation201609042020014853Copyright © Стрижевская А.М., Головня Е.Г., Кулешова И.С., Дзампаев А.З., Байкова В.Н., 20202020Стрижевская А.М., Головня Е.Г., Кулешова И.С., Дзампаев А.З., Байкова В.Н.Strizhevskaya A.M., Golovnya E.G., Kuleshova I.S., Dzampaeva A.Z., Baykova V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/161

В детской онкологии высокие дозы метотрексата (ВД Mtx) используются для лечения остеосаркомы (ОС), острого лимфобластного лейкоза и ряда других опухолей. В связи с высокой интра- и экстраиндивидуальной изменчивостью фармакокинетики Mtx необходимо проводить мониторинг его концентрации в сыворотке крови. Самым опасным явлением при терапии ВД Mtx является т.н. «отсроченная экскреция Mtx», «замедленное выведение Mtx». Их развитие многофакторное и непредсказуемое. В данной работе, имея большой фактический материал, была поставлена задача проанализировать фармакокинетику ВД Mtx при остеосаркоме у детей, выявить ее особенности, установить, однотипно ли протекают нарушения выведения Mtх, провести их количественный анализ.

In children oncology high doses of methotrexate (HD Mtx) use for treatment of osteosarcoma, acute lymphoblastic leukemia and many others tumors. Due to high intra- and interindividual Mtx pharmacokinetic variability it is essential perform monitoring its concentration in the saliva. The most dangerous phenomena in the case of HD Mtx are so-termed "delayed Mtx excretion", "prolonged Mtx excretion". Their development is multifactorial and unpredictable. Having big actual material we set task: analyze pharmacokinetics HD Mtx in case of osteosarcoma in children, determine its peculiarities, elucidate whether similar or not proceed disorders of Mtx excretion, perform their quantification.

детивысокие дозы метотрексатаонкологиятерапевтический лекарственный мониторингтоксико-кинетикатоксичностьchildrenhigh doses of Methotrexateoncologytherapeutic drug monitoringtoxicokineticstoxicitychildrenhigh doses of Methotrexateoncologytherapeutic drug monitoringtoxicokineticstoxicityReferencesКопосов П.В., Ковалев В.И., Ковалев Д.В. Профилактика и лечение осложнений химиотерапии злокачественных опухолей у детей: современные подходы. Руководство для врачей. М.: ООО «Клевер Принт», 2002; 73-78.Копосов П.В., Ковалев В.И., Ковалев Д.В. Профилактика и лечение осложнений химиотерапии злокачественных опухолей у детей: современные подходы. Руководство для врачей. М.: ООО «Клевер Принт», 2002; 73-78.Соколов А.В. Терапевтический лекарственный мониторинг. Качественная клиническая практика. 2002; 1: 78-88.Соколов А.В. Терапевтический лекарственный мониторинг. Качественная клиническая практика. 2002; 1: 78-88.Bacci G., Ferrari S., Longhi A. et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagentregimens of neoadjuvant chemotherapy. Oncol. Rep. 2003; 10: 4: 851-857.Bacci G., Ferrari S., Longhi A. et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagentregimens of neoadjuvant chemotherapy. Oncol. Rep. 2003; 10: 4: 851-857.Buchen S., Ngampolo D., Melton R.G. et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer. 2005; 92: 480-487.Buchen S., Ngampolo D., Melton R.G. et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer. 2005; 92: 480-487.Crews K.R., Liu T., Rodriguez-Galindo C. et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004; 100: 8: 1724-1733.Crews K.R., Liu T., Rodriguez-Galindo C. et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004; 100: 8: 1724-1733.Dalle J.H., Auvrignon A., Vassal G. et al. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002; 24: 4: 321-322.Dalle J.H., Auvrignon A., Vassal G. et al. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002; 24: 4: 321-322.Dalle J.H., Auvrignon A., Vassal G. et al. Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication. Arch Pediatr. 2001; 8: 10: 1078-1081.Dalle J.H., Auvrignon A., Vassal G. et al. Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication. Arch Pediatr. 2001; 8: 10: 1078-1081.Distel L., Neubauer S., Varon R., et al. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol. 2003; 41: 1: 44-48.Distel L., Neubauer S., Varon R., et al. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol. 2003; 41: 1: 44-48.Frei E., Jaffe N., Gem M. et al. Adjuvant Chemotherapy of Osteogenic Sarcoma: Progress and Perspectives. J. Nat. Cancer Inst. 1978; 60: 1: 3-10.Frei E., Jaffe N., Gem M. et al. Adjuvant Chemotherapy of Osteogenic Sarcoma: Progress and Perspectives. J. Nat. Cancer Inst. 1978; 60: 1: 3-10.Holmboe L. et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. British Journal of Clinical. Br J Clin Pharmacol. 2011;73: 1:106-114.Holmboe L. et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. British Journal of Clinical. Br J Clin Pharmacol. 2011;73: 1:106-114.Jaffe N., Gorlick R. High-Dose Methotrexate in Osteosarcoma: Let the Questions Surcease-Time for Final Acceptance. J. of Clin.Onc. 2008; 28: 27: 4365-4366.Jaffe N., Gorlick R. High-Dose Methotrexate in Osteosarcoma: Let the Questions Surcease-Time for Final Acceptance. J. of Clin.Onc. 2008; 28: 27: 4365-4366.Kang Min Lee et al. Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management. Cancer Res Treat. 2011; 43: 1: 67-70.Kang Min Lee et al. Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management. Cancer Res Treat. 2011; 43: 1: 67-70.Koomdee N., Hongeng S., Apibal S., et al. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2012; 13: 7: 3461-3464.Koomdee N., Hongeng S., Apibal S., et al. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2012; 13: 7: 3461-3464.Lennard L. Therapeutic drug monitoring of antimetabolic cytotxic drugs. Brit. J. Clin. Pharmacol. 1999; 47: 2: 131-143.Lennard L. Therapeutic drug monitoring of antimetabolic cytotxic drugs. Brit. J. Clin. Pharmacol. 1999; 47: 2: 131-143.Levêque D. et al. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev. Clin. Pharmacol. 2011: 4: 6: 743-750.Levêque D. et al. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev. Clin. Pharmacol. 2011: 4: 6: 743-750.Lingg R.M., Hempel G., Rots M.G. et al. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. 2003; 65: 345-378.Lingg R.M., Hempel G., Rots M.G. et al. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. 2003; 65: 345-378.Mahadeo K.M., Dhall G., Panigrahy A., Lastra C., Ettinger L.J. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr Hematol Oncol. 2010; 27: 1: 46-52.Mahadeo K.M., Dhall G., Panigrahy A., Lastra C., Ettinger L.J. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr Hematol Oncol. 2010; 27: 1: 46-52.Mittal R., Mottl H., Nemec J. Acute transient cerebral toxicity associated with administration of high-dose methotrexate. Med Princ Pract. 2005; 14: 3: 202-204.Mittal R., Mottl H., Nemec J. Acute transient cerebral toxicity associated with administration of high-dose methotrexate. Med Princ Pract. 2005; 14: 3: 202-204.Müller J., Kralovánszky J., Adleff V., et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res. 2008; 28: 5B: 3051-3054.Müller J., Kralovánszky J., Adleff V., et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res. 2008; 28: 5B: 3051-3054.Reid T., Yuen A., Catolico M., Carlson R.W. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993; 33: 1: 82-84.Reid T., Yuen A., Catolico M., Carlson R.W. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993; 33: 1: 82-84.Saland J.M., Leavey P.J., Bash R.O. et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002; 17: 10: 825-829.Saland J.M., Leavey P.J., Bash R.O. et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002; 17: 10: 825-829.Santucci R., Levêque D., Herbrecht R. Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol. 2010; 70: 5: 762-764.Santucci R., Levêque D., Herbrecht R. Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol. 2010; 70: 5: 762-764.Santucci R., Levêque D., Lescoute A., Kemmel V., Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010; 30: 3807-3810.Santucci R., Levêque D., Lescoute A., Kemmel V., Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010; 30: 3807-3810.Yamamoto K., Sawada Y., Matsushita Y., Moriwaki K., Bessho F., Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann. Pharmacother. 1997; 31: 1261-1262.Yamamoto K., Sawada Y., Matsushita Y., Moriwaki K., Bessho F., Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann. Pharmacother. 1997; 31: 1261-1262.Zarychanski R., Wlodarczyk K., Ariano R., Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J. Antimicrob. Chemother. 2006; 58: 228-230.Zarychanski R., Wlodarczyk K., Ariano R., Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J. Antimicrob. Chemother. 2006; 58: 228-230.

The authors declare that there are no conflicts of interest present.